share_log

和黃醫藥：自願性公告－和黃醫藥宣佈FRUTIGA III期研究的結果於《自然醫學 (Nature Medicine)》發表

HUTCHMED: VOLUNTARY ANNOUNCEMENT - HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine

Hong Kong Stock Exchange ·  Jun 3 08:00
Summary by Futu AI
和黃醫藥（HUTCHMED）宣布其FRUTIGA III期臨床試驗結果已於《自然·醫學》發表，並於2024年6月1日的美國臨床腫瘤學會年會上更新療效和生活質量數據。該研究評估了呋喹替尼與紫杉醇聯合療法對703名晚期胃癌或胃食管結合部患者的療效，顯示中位無進展生存期顯著改善，並在多個其他終點達到統計學意義的改善。呋喹替尼已在中國和美國獲批治療特定轉移性結直腸癌，且其聯合療法的中國新藥上市申請於2023年4月獲受理。和黃醫藥是一家專注於癌症和免疫性疾病治療的生物醫藥公司，已有三個藥物在中國上市，其中一個亦在美國上市。
和黃醫藥（HUTCHMED）宣布其FRUTIGA III期臨床試驗結果已於《自然·醫學》發表，並於2024年6月1日的美國臨床腫瘤學會年會上更新療效和生活質量數據。該研究評估了呋喹替尼與紫杉醇聯合療法對703名晚期胃癌或胃食管結合部患者的療效，顯示中位無進展生存期顯著改善，並在多個其他終點達到統計學意義的改善。呋喹替尼已在中國和美國獲批治療特定轉移性結直腸癌，且其聯合療法的中國新藥上市申請於2023年4月獲受理。和黃醫藥是一家專注於癌症和免疫性疾病治療的生物醫藥公司，已有三個藥物在中國上市，其中一個亦在美國上市。
HUTCHMED ANNOUNCED THE RESULTS OF ITS FRUTIGA PHASE III CLINICAL TRIAL PUBLISHED IN NATURE MEDICINE AND UPDATED EFFICACY AND QUALITY OF LIFE DATA AT THE ANNUAL MEETING OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY ON JUNE 1, 2024. THE STUDY EVALUATED THE EFFICACY OF FUQUINTINE-FORTIOL COMBINATION THERAPY IN 703 PATIENTS WITH LATE STAGE GASTRIC CANCER OR GASTROESOPHAGEAL COMBINATION, SHOWING SIGNIFICANT IMPROVEMENT IN MEDIAN PROGRESSION-FREE SURVIVAL AND STATISTICALLY SIGNIFICANT IMPROVEMENTS AT SEVERAL OTHER ENDPOINTS. Furuquinetine has been approved in China and the United States for the treatment of certain metastatic colorectal cancers, and the application for a new Chinese drug for its combination therapy was accepted in April 2023. Wah Wong Pharmaceuticals is a biopharmaceutical company focused on the treatment of cancer and immune diseases. Three drugs are listed in China, including one in the United States.
HUTCHMED ANNOUNCED THE RESULTS OF ITS FRUTIGA PHASE III CLINICAL TRIAL PUBLISHED IN NATURE MEDICINE AND UPDATED EFFICACY AND QUALITY OF LIFE DATA AT THE ANNUAL MEETING OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY ON JUNE 1, 2024. THE STUDY EVALUATED THE EFFICACY OF FUQUINTINE-FORTIOL COMBINATION THERAPY IN 703 PATIENTS WITH LATE STAGE GASTRIC CANCER OR GASTROESOPHAGEAL COMBINATION, SHOWING SIGNIFICANT IMPROVEMENT IN MEDIAN PROGRESSION-FREE SURVIVAL AND STATISTICALLY SIGNIFICANT IMPROVEMENTS AT SEVERAL OTHER ENDPOINTS. Furuquinetine has been approved in China and the United States for the treatment of certain metastatic colorectal cancers, and the application for a new Chinese drug for its combination therapy was accepted in April 2023. Wah Wong Pharmaceuticals is a biopharmaceutical company focused on the treatment of cancer and immune diseases. Three drugs are listed in China, including one in the United States.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.